The results of NONcNZO10/LTJ mouse studies enhance the potential of aFGF in treating skin wounds in diabetic patients, because researchers found that when exogenous heparin is not added in the formula, stable mutant aFGF may obtain similar therapeutic effects, but it has greater potential safety and cost advantages than wild-type aFGF proteins, and the reconstruction of fibroblast growth factor -1 (aFGF) is identified as a potential “second generation” therapy to promote the healing of skin wounds of diabetes (78). This evidence concerns the gene FGF1 and diabetes mellitus.